Viking Therapeutics, Inc. (NASDAQ:VKTX) headquartered in San Diego, will host a conference call for the investment community to discuss the 3Q20 earnings result on 28th October 2020 at 4:30 PM Eastern Time.
Those interested in listening to the conference call live via the Internet can visit www.vikingtherapeutics.com
Earnings Expectation
Viking Therapeutics, Inc. clinical-stage biopharmaceutical firm, is expected to report third quarter earnings results, after market close, on Wednesday 28th October 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.15 per share. Looking ahead, the full year loss are expected at $ 0.59 per share.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase II clinical trials to treat patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol. The companys lead drug candidate also includes VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery.
